KRASCENDO trial: Divarasib a second generation KRAS G12C inhibitor improves PFS and OS in mNSCLC compared to 1st Generation sotorasib. #ESMO2026

Abeid Athman (Omar).· @bin_abeid · X·2026-10-25 23:46· 1 天前评分70

正文 · 原文

KRASCENDO trial: Divarasib a second generation KRAS G12C inhibitor improves PFS and OS in mNSCLC compared to 1st Generation sotorasib. #ESMO2026
@curijoey @myESMO @darioT_ @OncBrothers

14 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Abeid Athman (Omar). · x.com